Citalopram

Publication Title: 
Obstetrics and Gynecology

OBJECTIVE: To describe the effects of six interventions for menopausal vasomotor symptoms relative to control in a pooled analysis, facilitating translation of the results for clinicians and symptomatic women. The Menopause Strategies: Finding Lasting Answers for Symptoms and Health network tested these interventions in three randomized clinical trials. METHODS: An analysis of pooled individual-level data from three randomized clinical trials is presented. Participants were 899 perimenopausal and postmenopausal women with at least 14 bothersome vasomotor symptoms per week.

Author(s): 
Guthrie, Katherine A.
LaCroix, Andrea Z.
Ensrud, Kristine E.
Joffe, Hadine
Newton, Katherine M.
Reed, Susan D.
Caan, Bette
Carpenter, Janet S.
Cohen, Lee S.
Freeman, Ellen W.
Larson, Joseph C.
Manson, JoAnn E.
Rexrode, Kathy
Skaar, Todd C.
Sternfeld, Barbara
Anderson, Garnet L.
Publication Title: 
The Cochrane Database of Systematic Reviews

BACKGROUND: This is an updated version of the Cochrane review published in 2005 on selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headache. The original review has been split in two parts and this review now only regards tension-type headache prevention. Another updated review covers migraine. Tension-type headache is the second most common disorder worldwide and has high social and economic relevance.

Author(s): 
Banzi, Rita
Cusi, Cristina
Randazzo, Concetta
Sterzi, Roberto
Tedesco, Dario
Moja, Lorenzo
Publication Title: 
Progress in Neuro-Psychopharmacology & Biological Psychiatry

OBJECTIVES: The "neurotrophin hypothesis" of depression posits a role of brain-derived neurotrophic factor (BDNF) in depression, although it is unknown whether BDNF is more involved in the etiology of depression or in the mechanism of action of antidepressants. It is also unknown whether pre-treatment serum BDNF levels predict antidepressant response. METHODS: Thirty un-medicated depressed subjects were treated with escitalopram (N=16) or sertraline (N=14) for 8 weeks. Twenty-five of the depressed subjects completed 8 weeks of antidepressant treatment and had analyzable data.

Author(s): 
Wolkowitz, Owen M.
Wolf, Jessica
Shelly, Wendy
Rosser, Rebecca
Burke, Heather M.
Lerner, George K.
Reus, Victor I.
Nelson, J. Craig
Epel, Elissa S.
Mellon, Synthia H.
Publication Title: 
Translational Psychiatry

Transcriptional differences in interleukin-11 (IL11) after antidepressant treatment have been found to correspond to clinical response in major depressive disorder (MDD) patients. Expression differences were partly mediated by a single-nucleotide polymorphism (rs1126757), identified as a predictor of antidepressant response as part of a genome-wide association study.

Author(s): 
Powell, T. R.
Smith, R. G.
Hackinger, S.
Schalkwyk, L. C.
Uher, R.
McGuffin, P.
Mill, J.
Tansey, K. E.
Publication Title: 
The International Journal of Neuropsychopharmacology

Variation in the serotonin transporter gene (5-HTT; SERT; SLC6A4) has been suggested to pharmacogenetically drive interindividual differences in antidepressant treatment response. In the present analysis, a 'pharmaco-epigenetic' approach was applied by investigating the influence of DNA methylation patterns in the 5-HTT transcriptional control region on antidepressant treatment response.

Author(s): 
Domschke, Katharina
Tidow, Nicola
Schwarte, Kathrin
Deckert, J¸rgen
Lesch, Klaus-Peter
Arolt, Volker
Zwanzger, Peter
Baune, Bernhard T.
Publication Title: 
Molecular Psychiatry

Bipolar disorder (BD) is a chronic psychiatric disorder of public health importance affecting >1% of the Swedish population. Despite progress, patients still suffer from chronic mood switches with potential severe consequences. Thus, early detection, diagnosis and initiation of correct treatment are critical.

Author(s): 
Hayashi, A.
Le Gal, K.
Sˆdersten, K.
Vizlin-Hodzic, D.
≈gren, H.
Funa, K.
Publication Title: 
Psychoneuroendocrinology

OBJECTIVE: Epigenetic regulation investigated by methylation tests has been associated with pathogenesis and treatment response in depressive disorders. However, these hypotheses have rarely been tested in patients with acute coronary syndrome (ACS) vulnerable to depression. This study aimed to investigate whether brain derived neurotrophic factor (BDNF) methylation status is associated with occurrence and treatment response of depressive disorder in ACS. METHODS: Of 969 patients with recently developed ACS were recruited at baseline, 711 were followed 1 year thereafter.

Author(s): 
Kim, Jae-Min
Stewart, Robert
Kang, Hee-Ju
Bae, Kyung-Yeol
Kim, Sung-Wan
Shin, Il-Seon
Hong, Young Joon
Ahn, Youngkeun
Jeong, Myung Ho
Yoon, Jin-Sang
Publication Title: 
Menopause (New York, N.Y.)

OBJECTIVE: This report describes the Menopausal Strategies: Finding Lasting Answers to Symptoms and Health network and methodological issues addressed in designing and implementing vasomotor symptom trials. METHODS: Established in response to a National Institutes of Health request for applications, the network was charged with conducting rapid throughput randomized trials of novel and understudied available interventions postulated to alleviate vasomotor and other menopausal symptoms.

Author(s): 
Newton, Katherine M.
Carpenter, Janet S.
Guthrie, Katherine A.
Anderson, Garnet L.
Caan, Bette
Cohen, Lee S.
Ensrud, Kristine E.
Freeman, Ellen W.
Joffe, Hadine
Sternfeld, Barbara
Reed, Susan D.
Sherman, Sheryl
Sammel, Mary D.
Kroenke, Kurt
Larson, Joseph C.
LaCroix, Andrea Z.
Publication Title: 
Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology

Approximately one-third of persons with depression do not respond to antidepressant monotherapy. Studies suggest that atypical antipsychotic augmentation may benefit these patients. We investigated the longer-term efficacy of risperidone augmentation of serotonin-selective reuptake inhibitor treatment for resistant depression. In 57 in- and outpatient centers in three countries, we conducted a three-phase study with 4-6 weeks of open-label citalopram monotherapy, 4-6 weeks of open-label risperidone augmentation, and a 24-week double-blind, placebo-controlled discontinuation phase.

Author(s): 
Rapaport, Mark Hyman
Gharabawi, Georges M.
Canuso, Carla M.
Mahmoud, Ramy A.
Keller, Martin B.
Bossie, Cynthia A.
Turkoz, Ibrahim
Lasser, Robert A.
Loescher, Amy
Bouhours, Philippe
Dunbar, Fiona
Nemeroff, Charles B.
Publication Title: 
The American Journal of Psychiatry

OBJECTIVE: Major depressive disorder is characterized by impaired reward processing, possibly due to dysfunction in the basal ganglia. However, few neuroimaging studies of depression have distinguished between anticipatory and consummatory phases of reward processing. Using functional MRI (fMRI) and a task that dissociates anticipatory and consummatory phases of reward processing, the authors tested the hypothesis that individuals with major depression would show reduced reward-related responses in basal ganglia structures.

Author(s): 
Pizzagalli, Diego A.
Holmes, Avram J.
Dillon, Daniel G.
Goetz, Elena L.
Birk, Jeffrey L.
Bogdan, Ryan
Dougherty, Darin D.
Iosifescu, Dan V.
Rauch, Scott L.
Fava, Maurizio

Pages

Subscribe to RSS - Citalopram